Journal
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volume 10, Issue 7, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2022-004616
Keywords
Immunotherapy; Tumor Microenvironment; CD8-Positive T-Lymphocytes; Drug Therapy; Combination
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [26221005, 20H03534, 21H02785, 18K08309, 15K09783, 21K15602]
- Japan Agency for Medical Research and Development (AMED)(P-CREATE) [20cm0106305h0005]
- Japan Science and Technology Agency (JST) Exploratory Research for Advanced Technology (ERATO) Suematsu gas biology project
- Kobayashi Foundation for Cancer Research
- GSK Japan Research Grant 2021
- Nihon University
Ask authors/readers for more resources
This study investigated the immunological roles of SCD1 in cancer immune response, finding that SCD1 inhibition augments antitumor T cells and enhances the therapeutic effects of anti-PD-1 antibody. High SCD1 expression was observed in a non-T cell-inflamed subtype of human colon cancer, and serum SCD1 related fatty acids were correlated with response rates and prognosis of non-small lung cancer patients following anti-PD-1 antibody treatment. Therefore, SCD1 is a promising target for improving cancer immunotherapies.
Background Understanding the mechanisms of non-T cell inflamed tumor microenvironment (TME) and their modulation are important to improve cancer immunotherapies such as immune checkpoint inhibitors. The involvement of various immunometabolisms has recently been indicated in the formation of immunosuppressive TME. In this study, we investigated the immunological roles of stearoyl-CoA desaturase 1 (SCD1), which is essential for fatty acid metabolism, in the cancer immune response. Methods We investigated the roles of SCD1 by inhibition with the chemical inhibitor or genetic manipulation in antitumor T cell responses and the therapeutic effect of anti-programmed cell death protein 1 (anti-PD-1) antibody using various mouse tumor models, and their cellular and molecular mechanisms. The roles of SCD1 in human cancers were also investigated by gene expression analyses of colon cancer tissues and by evaluating the related free fatty acids in sera obtained from patients with non-small cell lung cancer who were treated with anti-PD-1 antibody. Results Systemic administration of a SCD1 inhibitor in mouse tumor models enhanced production of CCL4 by cancer cells through reduction of Wnt/beta-catenin signaling and by CD8(+) effector T cells through reduction of endoplasmic reticulum stress. It in turn promoted recruitment of dendritic cells (DCs) into the tumors and enhanced the subsequent induction and tumor accumulation of antitumor CD8(+) T cells. SCD1 inhibitor was also found to directly stimulate DCs and CD8(+) T cells. Administration of SCD1 inhibitor or SCD1 knockout in mice synergized with an anti-PD-1 antibody for its antitumor effects in mouse tumor models. High SCD1 expression was observed in one of the non-T cell-inflamed subtypes in human colon cancer, and serum SCD1 related fatty acids were correlated with response rates and prognosis of patients with non-small lung cancer following anti-PD-1 antibody treatment. Conclusions SCD1 expressed in cancer cells and immune cells causes immunoresistant conditions, and its inhibition augments antitumor T cells and therapeutic effects of anti-PD-1 antibody. Therefore, SCD1 is an attractive target for the development of new diagnostic and therapeutic strategies to improve current cancer immunotherapies including immune checkpoint inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available